SOLA Biosciences

Executive Summary

SOLA Biosciences is a San Diego-based biotechnology company pioneering novel RNA-based therapies for debilitating neurodegenerative diseases like ALS and Parkinson's. Founded in 2018, the company leverages its proprietary JUMP70 platform to target the root cause of these disorders: protein misfolding and aggregation. By addressing pathological protein clumping, SOLA aims to halt or reverse disease progression, offering a potential disease-modifying approach where current treatments only manage symptoms. The JUMP70 platform is designed to deliver RNA therapeutics that selectively modulate protein homeostasis, a novel mechanism that could be broadly applicable across multiple neurodegenerative conditions. Despite being in the preclinical stage, SOLA has generated encouraging in vitro and in vivo data demonstrating target engagement and neuroprotection. The company is actively advancing toward IND-enabling studies for its lead candidate, with a focus on ALS due to clear biomarkers and high unmet need. While competition in the RNA therapy space is intense, SOLA's differentiated approach targeting protein misfolding could carve a unique therapeutic niche. The company remains privately funded and has not disclosed financial details, but its innovative platform and clear indication focus position it as a compelling early-stage biotech. Continued progress in preclinical models and potential partnership interest are key near-term value drivers.

Upcoming Catalysts (preview)

• Q4 2026Preclinical efficacy data in ALS model50% success
• H1 2027IND submission for lead candidate30% success
• TBDStrategic partnership or licensing deal40% success